lutetium has been researched along with Xerostomia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, YI; Lee, DY | 1 |
| Beheshti, A; Bruchertseifer, F; D'Alessandria, C; Eiber, M; Feuerecker, B; Gafita, A; Gschwend, JE; Heck, M; Knorr, K; Kratochwil, C; Morgenstern, A; Pickhard, A; Retz, M; Seidl, C; Tauber, R; Weber, WA | 1 |
| Bins, A; Braat, A; de Keizer, B; Hunting, J; Krijger, G; Lam, M; Mehra, N; van Kalmthout, L; van Leeuwaarde, R; Ververs, T | 1 |
1 review(s) available for lutetium and Xerostomia
| Article | Year |
|---|---|
Effects of
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Leukopenia; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Thrombocytopenia; Treatment Outcome; Xerostomia | 2022 |
2 other study(ies) available for lutetium and Xerostomia
| Article | Year |
|---|---|
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome; Xerostomia | 2021 |
First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Dipeptides; Fatigue; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Netherlands; Pain; Pain Measurement; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; Xerostomia | 2019 |